Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. WST
WST logo

WST Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy West Pharmaceutical Services Inc (WST) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
327.950
1 Day change
1.35%
52 Week Range
336.820
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

West Pharmaceutical Services Inc (WST) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong bullish momentum with hedge funds significantly increasing their positions, positive analyst upgrades, and a favorable long-term growth outlook in the injectables market. Despite the lack of recent news or Congress trading data, the technical indicators and options sentiment align with a positive investment opportunity.

Technical Analysis

The stock is showing bullish momentum with moving averages in a positive alignment (SMA_5 > SMA_20 > SMA_200). The RSI is neutral at 55.599, and the MACD is below zero but negatively expanding. The stock closed above its pivot level (324.848) and is near its first resistance level (334.875), suggesting potential for further upward movement.

Options Data

Neutral
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
9

Positive Catalysts

  • Hedge funds have increased their buying by 196.32% over the last quarter.

  • Analysts have upgraded the stock with increased price targets, citing strong growth in high-value products and injectables.

  • The stock has an 80% chance of gaining 3.25% in the next day and 2.18% in the next week.

Neutral/Negative Catalysts

  • MACD is negatively expanding, which could indicate short-term bearish pressure.

  • No recent news or Congress trading data to provide additional sentiment insights.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have been upgrading the stock consistently. Wolfe Research upgraded to Outperform with a $375 price target, and Citi raised its price target to $400. Analysts highlight strong Q1 performance and long-term growth potential in injectables.

Wall Street analysts forecast WST stock price to rise
12 Analyst Rating
Wall Street analysts forecast WST stock price to rise
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 323.590
sliders
Low
285
Averages
348.7
High
375
Current: 323.590
sliders
Low
285
Averages
348.7
High
375
Barclays
upgrade
AI Analysis
2026-06-09
Reason
Barclays
Price Target
AI Analysis
2026-06-09
upgrade
Reason
Barclays upgraded West…
Wolfe Research
Mike Polark
Peer Perform
to
Outperform
upgrade
$375
2026-06-01
Reason
Wolfe Research
Mike Polark
Price Target
$375
2026-06-01
upgrade
Peer Perform
to
Outperform
Reason
As previously reported, Wolfe Research analyst Mike Polark upgraded West Pharmaceutical to Outperform from Peer Perform with a $375 price target. Q1 was \"juicy good,\" driven by continued GLP1 growth and a return to significant growth in \"everything else\" within the high-value products category, the analyst tells investors. West is levered to injectables which are still growing and widely projected to grow for years to come, the analyst added.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for WST
Unlock Now

People Also Watch